Ceftazidime
- Product NDC
- 25021-127
- Requested package NDC
- 25021-127-20
- 11-digit product format
- 250210127
- Labeler code
- 25021
- Product ID
- 25021-127_57ce314f-eda1-4438-8a50-2010d4d8aefd
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- ceftazidime
- Dosage form
- INJECTION, POWDER, FOR SOLUTION
- Route
- INTRAMUSCULAR; INTRAVENOUS
- Labeler
- Sagent Pharmaceuticals
- Application
- ANDA062640
- Marketing category
- ANDA
- Marketing start
- 2008-05-15
- Substance
- CEFTAZIDIME
- Active strength
- 1 g/1
- Pharmacologic classes
- Cephalosporin Antibacterial [EPC], Cephalosporins [CS]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A062640-001 | CEFTAZIDIME | CEFTAZIDIME | 500MG/VIAL | INJECTABLE / INJECTION | 1985-11-20 | ||
| A062640-002 | CEFTAZIDIME | CEFTAZIDIME | 1GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1985-11-20 |
| A062640-003 | CEFTAZIDIME | CEFTAZIDIME | 2GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1985-11-20 |
| A062640-004 | CEFTAZIDIME | CEFTAZIDIME | 6GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1992-02-03 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A062640-002 | AP |
| A062640-003 | AP |
| A062640-004 | AP |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A062640-001 | CEFTAZIDIME | 500MG/VIAL | INJECTABLE / INJECTION | 1985-11-20 | d4dbc9d85df4… | ||
| 2026-11-14 07:37:17 | 2026-10 | A062640-002 | CEFTAZIDIME | 1GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1985-11-20 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A062640-003 | CEFTAZIDIME | 2GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1985-11-20 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A062640-004 | CEFTAZIDIME | 6GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1992-02-03 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A062640-001 | CEFTAZIDIME | 500MG/VIAL | INJECTABLE / INJECTION | 1985-11-20 | c2088c7a36db… | ||
| 2026-10-15 13:18:30 | 2026-09 | A062640-002 | CEFTAZIDIME | 1GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1985-11-20 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A062640-003 | CEFTAZIDIME | 2GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1985-11-20 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A062640-004 | CEFTAZIDIME | 6GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1992-02-03 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A062640-001 | CEFTAZIDIME | 500MG/VIAL | INJECTABLE / INJECTION | 1985-11-20 | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | A062640-002 | CEFTAZIDIME | 1GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1985-11-20 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A062640-003 | CEFTAZIDIME | 2GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1985-11-20 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A062640-004 | CEFTAZIDIME | 6GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1992-02-03 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A062640-001 | CEFTAZIDIME | 500MG/VIAL | INJECTABLE / INJECTION | 1985-11-20 | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | A062640-002 | CEFTAZIDIME | 1GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1985-11-20 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A062640-003 | CEFTAZIDIME | 2GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1985-11-20 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A062640-004 | CEFTAZIDIME | 6GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1992-02-03 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A062640-001 | CEFTAZIDIME | 500MG/VIAL | INJECTABLE / INJECTION | 1985-11-20 | 011fe1cb6892… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A062640-002 | CEFTAZIDIME | 1GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1985-11-20 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A062640-003 | CEFTAZIDIME | 2GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1985-11-20 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A062640-004 | CEFTAZIDIME | 6GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1992-02-03 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A062640-001 | CEFTAZIDIME | 500MG/VIAL | INJECTABLE / INJECTION | 1985-11-20 | 31067a03dcf5… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A062640-002 | CEFTAZIDIME | 1GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1985-11-20 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A062640-003 | CEFTAZIDIME | 2GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1985-11-20 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A062640-004 | CEFTAZIDIME | 6GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1992-02-03 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A062640-001 | CEFTAZIDIME | 500MG/VIAL | INJECTABLE / INJECTION | 1985-11-20 | 6a471c1ec25d… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A062640-002 | CEFTAZIDIME | 1GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1985-11-20 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A062640-003 | CEFTAZIDIME | 2GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1985-11-20 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A062640-004 | CEFTAZIDIME | 6GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1992-02-03 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A062640-001 | CEFTAZIDIME | 500MG/VIAL | INJECTABLE / INJECTION | 1985-11-20 | fd3edfee7708… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A062640-002 | CEFTAZIDIME | 1GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1985-11-20 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A062640-003 | CEFTAZIDIME | 2GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1985-11-20 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A062640-004 | CEFTAZIDIME | 6GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1992-02-03 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A062640-001 | CEFTAZIDIME | 500MG/VIAL | INJECTABLE / INJECTION | 1985-11-20 | b8a1b40f171c… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A062640-002 | CEFTAZIDIME | 1GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1985-11-20 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A062640-003 | CEFTAZIDIME | 2GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1985-11-20 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A062640-004 | CEFTAZIDIME | 6GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1992-02-03 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A062640-001 | CEFTAZIDIME | 500MG/VIAL | INJECTABLE / INJECTION | 1985-11-20 | 03ed91905a0d… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A062640-002 | CEFTAZIDIME | 1GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1985-11-20 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A062640-003 | CEFTAZIDIME | 2GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1985-11-20 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A062640-004 | CEFTAZIDIME | 6GM/VIAL | INJECTABLE / INJECTION | AP | RS | 1992-02-03 | 03ed91905a0d… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A062640-002 | AP | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A062640-003 | AP | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A062640-004 | AP | 1 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A062640-002 | AP | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A062640-003 | AP | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A062640-004 | AP | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A062640-002 | AP | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A062640-003 | AP | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A062640-004 | AP | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A062640-002 | AP | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A062640-003 | AP | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A062640-004 | AP | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A062640-002 | AP | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A062640-003 | AP | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A062640-004 | AP | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A062640-002 | AP | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A062640-003 | AP | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A062640-004 | AP | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A062640-002 | AP | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A062640-003 | AP | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A062640-004 | AP | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A062640-002 | AP | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A062640-003 | AP | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A062640-004 | AP | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A062640-002 | AP | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A062640-003 | AP | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A062640-004 | AP | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A062640-002 | AP | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A062640-003 | AP | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A062640-004 | AP | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A062640-002 | AP | 1 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A062640-003 | AP | 1 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A062640-004 | AP | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A062640-002 | AP | 1 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A062640-003 | AP | 1 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A062640-004 | AP | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A062640-002 | AP | 1 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A062640-003 | AP | 1 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A062640-004 | AP | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A062640-002 | AP | 1 | d06236e962d9… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Ceftazidime
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| CEFTAZIDIME | 1 g/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 9M416Z9QNR | Internal UNII lookup |
Harmonized RxCUI identifiers#
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| 112c5457-8d71-49f5-b531-9761d7d38c93 | Available on FDA.report |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| fb7d24f2-fcd1-4dc6-b9d0-b1f65bfffab5 | Product name | 1 | 20150409 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 25021-127-20 | Ceftazidime | 1 in 1 VIAL | INJECTION, POWDER, FOR SOLUTION | 1 | 11 | |
| 25021-127-20 | Ceftazidime | 25 in 1 CARTON | INJECTION, POWDER, FOR SOLUTION | 25 | 11 |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 25021-127-20 | EA - Each | 25021-127 | 21a42dad-cda4-4d28-bd57-33adc07e6c76 | 1 | 2012-07-24 |
| 25021-127-66 | EA - Each | 25021-127 | 44f7f396-7806-414a-8bd4-0e06d8c18e25 | 1 | 2015-07-20 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| ceftazidime | ACTIVE INGREDIENT | 9M416Z9QNR | CEFTAZIDIME INJECTION, POWDER, FOR SOLUTION [SAGENT PHARMACEUTICALS] | 6 | |
| CEFTAZIDIME ANHYDROUS | ACTIVE MOIETY | DZR1ENT301 | CEFTAZIDIME INJECTION, POWDER, FOR SOLUTION [SAGENT PHARMACEUTICALS] | 6 | |
| sodium carbonate | INACTIVE INGREDIENT | 45P3261C7T | CEFTAZIDIME INJECTION, POWDER, FOR SOLUTION [SAGENT PHARMACEUTICALS] | 6 | |
| ceftazidime | ACTIVE INGREDIENT | 9M416Z9QNR | CEFTAZIDIME INJECTION, POWDER, FOR SOLUTION [SAGENT PHARMACEUTICALS] | 2 | |
| CEFTAZIDIME ANHYDROUS | ACTIVE MOIETY | DZR1ENT301 | CEFTAZIDIME INJECTION, POWDER, FOR SOLUTION [SAGENT PHARMACEUTICALS] | 2 | |
| sodium carbonate | INACTIVE INGREDIENT | 45P3261C7T | CEFTAZIDIME INJECTION, POWDER, FOR SOLUTION [SAGENT PHARMACEUTICALS] | 2 |
DailyMed Dashboard NDC Coverage#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Ceftazidime | CEFTAZIDIME | Sagent Pharmaceuticals | 112c5457-8d71-49f5-b531-9761d7d38c93 | 2026-08-03 | Warnings, Adverse reactions | 062640 ANDA062640 25021-127-20 25021-127 25021012720 |
| Ceftazidime | CEFTAZIDIME | WG Critical Care, LLC | 22d6534c-4488-48a1-8d78-e2fb908259de | 2026-06-24 | Boxed warning, Warnings, Adverse reactions | 062640 ANDA062640 |
| Ceftazidime | CEFTAZIDIME | Sagent Pharmaceuticals | aec64360-8452-4987-a366-a5a4f8762ab6 | 2024-01-03 | Warnings, Adverse reactions | 062640 ANDA062640 |
| Ceftazidime | CEFTAZIDIME | WG Critical Care, LLC | bcc81df2-20e3-4738-bfcf-301da883c1d9 | 2023-09-11 | Warnings, Adverse reactions | 062640 ANDA062640 |
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 1659283 | cefTAZidime 1 GM Injection | PSN | 112c5457-8d71-49f5-b531-9761d7d38c93 | 11 |
| 1659287 | cefTAZidime 2 GM Injection | PSN | 112c5457-8d71-49f5-b531-9761d7d38c93 | 11 |
| 1659283 | ceftazidime 1000 MG Injection | SCD | 112c5457-8d71-49f5-b531-9761d7d38c93 | 11 |
| 1659287 | ceftazidime 2000 MG Injection | SCD | 112c5457-8d71-49f5-b531-9761d7d38c93 | 11 |
| 1659283 | ceftazidime (as ceftazidime pentahydrate) 1000 MG Injection | SY | 112c5457-8d71-49f5-b531-9761d7d38c93 | 11 |
| 1659287 | ceftazidime (as ceftazidime pentahydrate) 2000 MG Injection | SY | 112c5457-8d71-49f5-b531-9761d7d38c93 | 11 |
| 1659283 | ceftazidime 1 GM Injection | SY | 112c5457-8d71-49f5-b531-9761d7d38c93 | 11 |
| 1659287 | ceftazidime 2 GM Injection | SY | 112c5457-8d71-49f5-b531-9761d7d38c93 | 11 |
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|---|
| 25021-127-20 | 25021012720 | 25 VIAL in 1 CARTON (25021-127-20) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL | 25 vial | 2008-05-15 | 0000-00-00 | No | No | Current |